Clovis Oncology, Inc. (CLVS) was a big mover last session, as the company saw its shares rise by over 7% on the day. The move came on the back of solid volume too, as far more shares changed hands than in a normal session. The uptrend is continuing for this biotechnology company, as the stock rose nearly 8% in the past one-month time period.
The company has seen a mixed track record when it comes to estimate revisions over the past few weeks (1 increase, 2 decreases) and the earnings consensus hasn’t been in trend either. This recent price action is certainly encouraging, so make sure to keep a close watch on this firm in the near future.
Clovis Oncology currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Some better performing biotechnology stocks include Affymetrix Inc. (AFFX), Biogen Idec Inc. (BIIB) and Gilead Sciences Inc. (GILD). All these carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>